Glp-1 Analogue Peptide For Glp-1 Receptor Activation

Glucagon-like peptide-1 (GLP-1)receptoragonists, also known asGLP-1agonists andGLP-1RAs, are a class of medications that activate theGLP-1receptor, causing reduced blood sugar, reduced appetite, and reduced energy intake.GLP-1analogs are molecules that are structurally almost identical to the endogenousGLP-1hormone. Incretin mimetics are substances that mimic the actions of incretin ...

We describe twoGLP-1analogueswith prolonged signaling relative toGLP-1itself but with varied abilities to inducereceptorinternalization. Cryogenic electron microscopy structures of these twoanaloguesbound to theGLP-1R provide insights into the molecular mechanisms ofpeptide-mediated agonism.

Summary Glucagon-like peptide-1 (GLP-1)receptoragonists are incretinanaloguesthat promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.

GLP-1peptidesare synthetic analogs of glucagon-like peptide-1, an incretin hormone secreted by L-cells in the small intestine in response to nutrient intake. Thesepeptidesbind toGLP-1receptorsin the pancreas, hypothalamus, and gastrointestinal tract.

It seems likely that the resolution ofGLP-1receptorstructures and enhanced understanding of the complexity ofpeptidereceptorbinding andactivation, together with extensive knowledge gleaned from studies ofreceptormutagenesis, trafficking, and signaling, may enable development of more efficacious and selective small-molecule andpeptide...

The increasing prevalence of type 2 diabetes presents a major global health challenge. Glucagon-like peptide-1 (GLP-1)receptoragonists offer glycemic control, weight loss, and cardiovascular benefits but are limited by rapid enzymatic degradation and short half-life. Semaglutide, modified with a C18 diacid, extends its half-life to one week.